AMENDMENT NO. 1 TO AMENDED AND RESTATED EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • November 19th, 2010 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus
This Amendment No. 1 (“Amendment No. 1”) to the Amended and Restated Exclusive Sublicense Agreement (“Agreement”) is entered into on November 1, 2010 (“Effective Date”) between BioMimetic Therapeutics, Inc. (“BMTI”), a Delaware corporation (formerly known as BioMimetic Pharmaceuticals, Inc.) and Luitpold Pharmaceuticals, Inc. (“Luitpold”), a New York corporation (each, individually, a “Party” and, collectively, the “Parties”).
AMENDMENT NO. 1 TO AGREEMENT TERMINATING RESEARCH, DEVELOPMENT AND MARKETING AGREEMENTDevelopment and Marketing Agreement • November 19th, 2010 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus
This AMENDMENT NO. 1 (“Amendment No. 1”) to the AGREEMENT TERMINATING RESEARCH, DEVELOPMENT AND MARKETING AGREEMENT (“Termination Agreement”), is entered into as of November 1, 2010, between BioMimetic Therapeutics, Inc., a Delaware corporation (formerly known as BioMimetic Pharmaceuticals, Inc.) (“BMTI”), and Luitpold Pharmaceuticals, Inc., a New York corporation (“Luitpold”).
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 19th, 2010 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus
This Amendment No. 1 (“Amendment No. 1”) to the Asset Purchase Agreement (“Asset Purchase Agreement”) is entered into as of November 1, 2010 (“Effective Date”) between BioMimetic Therapeutics, Inc. (“BMTI”), a Delaware corporation (formerly known as BioMimetic Pharmaceuticals, Inc.) and Luitpold Pharmaceuticals, Inc. (“Luitpold”), a New York corporation (each, individually, a “Party” and, collectively, the “Parties”).
